Despite millions of doses of antiretroviral (ARV) drugs being stored in a Nairobi warehouse, clinics across Kenya are struggling to supply patients with more than a month’s worth of medication.
This shortage has left many HIV patients in a state of uncertainty, as the freeze on U.S. foreign aid continues to disrupt the distribution of life-saving treatments.
Reports indicate that HIV patients, who previously received a six-month supply of medication, are now being given only enough for one month.
Compounding the issue, the closure of specialized clinics for key populations has led to a growing number of people defaulting on their ARV medication.
The National Empowerment Network of People Living with HIV/AIDS in Kenya (NEPHAK) has raised concerns that adolescents are among the most affected, with stigma driving many away from seeking treatment.
While some counties have integrated HIV services into general healthcare, patients report that critical support systems remain inadequate, leaving them anxious about their future.
Funding Crisis and Stalled Distribution
Although the U.S. State Department issued a waiver to exempt HIV treatment from the aid freeze, logistical challenges persist.
The USAID payment system in Kenya remains inactive, preventing contractors from resuming operations.
Mackenzie Knowles-Coursin, a former USAID official, revealed that the Nairobi warehouse holds $34 million worth of medical supplies, including 2.5 million bottles of ARVs.
However, a Kenyan government document highlights that the lack of funding has stalled distribution, which requires an additional $10 million to proceed.
The Mission for Essential Drugs and Supplies (MEDS), a Christian charity responsible for distributing the medication to 2,000 clinics nationwide, has been forced to halt deliveries due to the financial shortfall.
Government’s assurance
Health Cabinet Secretary, Deborah Barasa, has assured the public that the government is working to release funds within two to four weeks.
Meanwhile, Finance Cabinet Secretary John Mbadi indicated that emergency funding may be allocated in the upcoming budget.
In the United States, lawsuits challenging the Trump administration’s aid cuts are making their way through the courts. Secretary of State Marco Rubio confirmed that over 80% of USAID programs have been canceled, further exacerbating the crisis.
Kenya has the world’s seventh-largest HIV-positive population, with approximately 1.4 million people living with the virus.
The President’s Emergency Plan for AIDS Relief (PEPFAR) funds roughly 40% of the country’s HIV treatment program.
However, stocks of essential HIV drugs, including Dolutegravir and Nevirapine, are running critically low.
In some clinics, patients are receiving only one-week refills, heightening concerns about long-term access to treatment.
As delays persist, thousands of Kenyan HIV patients remain in limbo, relying on government intervention or a policy shift from the U.S. to restore the flow of life-saving medication.
